Riding the Digital Health Wave: The L.E.K. Digital Excellence Framework

Japan’s nationwide policy-level shifts are affecting medical device volume and pricing in an increasingly competitive market.

Companies need to understand Japan’s pricing system and anticipate and plan for potential challenges both in advance of and subsequent to launch. 

Japan has continued to ensure reasonably favorable pricing and access for innovative drugs, biosimilars have received surprisingly little attention from…

After more than 25 years of investment, commercialization of gene therapies (GTs) has reached a pivotal point.

The COVID-19 crisis has had a strongly negative impact on the MTP sector, as it has on many other parts of the Australian economy.

COVID-19’s impact is first and foremost a global humanitarian crisis that has thrown us into uncharted territory, and we extend our sympathies to all who…

There is no doubt that COVID-19 has had a severe impact on the US healthcare ecosystem (as well as the rest of the economy) as providers have focused on…

Providers are on high alert due to the global impact of COVID-19. Current and potential future waves of infections, lockdowns and reopenings — and their…

Skyrocketing medical costs, clinical variation and outcomes that underindex those of other developed nations have risen to the forefront as key issues…

The following materials provide a snapshot of the unprecedented scope and speed of biopharma’s therapeutics research and development (R&D) response to…

The Future of the Healthcare Industry: Q&A with L.E.K. Consulting's Evan Zeng

Sej Brar describes what it takes to reshape and transform the strategic relevance of the medical affairs function.